HRP20160328T1 - Tritokvalin za uporabu u liječenju cistične fibroze - Google Patents
Tritokvalin za uporabu u liječenju cistične fibroze Download PDFInfo
- Publication number
- HRP20160328T1 HRP20160328T1 HRP20160328TT HRP20160328T HRP20160328T1 HR P20160328 T1 HRP20160328 T1 HR P20160328T1 HR P20160328T T HRP20160328T T HR P20160328TT HR P20160328 T HRP20160328 T HR P20160328T HR P20160328 T1 HRP20160328 T1 HR P20160328T1
- Authority
- HR
- Croatia
- Prior art keywords
- tritoqualine
- cystic fibrosis
- use according
- day
- complications
- Prior art date
Links
- IRGJVQIJENCTQF-UHFFFAOYSA-N tritoqualine Chemical compound CN1CCC2=CC=3OCOC=3C(OC)=C2C1C1C2=C(OCC)C(OCC)=C(OCC)C(N)=C2C(=O)O1 IRGJVQIJENCTQF-UHFFFAOYSA-N 0.000 title claims 12
- 201000003883 Cystic fibrosis Diseases 0.000 title claims 7
- 229960002634 tritoqualine Drugs 0.000 title claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 210000002345 respiratory system Anatomy 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 206010004659 Biliary cirrhosis Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000035467 Pancreatic insufficiency Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000028347 Sinus disease Diseases 0.000 claims 1
- 208000019902 chronic diarrheal disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 210000002249 digestive system Anatomy 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 230000005976 liver dysfunction Effects 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 208000015768 polyposis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (8)
1. Tritokvalin za uporabu u liječenju cistične fibroze ili barem jedne od komplikacija povezanih sa cističnom fibrozom.
2. Tritokvalin za uporabu prema zahtjevu 1, gdje se komplikacije cistične fibroze izabiru između infekcije ili upalnih poremećaja.
3. Tritokvalin za uporabu prema zahtjevu 1 ili 2, gdje se komplikacije cistične fibroze izabiru između infekcije ili upalnih poremećaja dišnog sustava, gušterače, probavnog sustava, žlijezda znojnica ili drugih egzokrinih tkiva.
4. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-3, gdje se komplikacije cistične fibroze izabiru između teške kronične bolesti pluća, insuficijencije gušterače, nazalne polipoze, pansinusitisa, kronične dijareje, pankreatitisa, ciroze ili drugih oblika disfunkcije jetre, bolesti sinusa, dijabetesa ili hepatobilijarnih problema, specifičnije fokalne bilijarne ciroze, bilijarne opstrukcije i progresivne periportalne fibroze.
5. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-4, u liječenju bolesti cistične fibroze i/ili bilo koje od komplikacija povezanih s dišnim putovima ili nazalnim komplikacijama.
6. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-5, gdje se tritokvalin primjenjuje subjektu u dozi od 1 mg-4 g/dan.
7. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-6, gdje se tritokvalin primjenjuje subjektu u dozi od 1, 5, 10, 20, 30, 50, 100, 200, 300, 400, 500, ili 600 mg/dan.
8. Tritokvalin za uporabu prema bilo kojem od zahtjeva 1-6, gdje se tritokvalin primjenjuje subjektu u dozi od 1 g/dan, 2 g/dan, 3 g/dan ili 4 g/dan.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305487.6A EP2659890A1 (en) | 2012-04-30 | 2012-04-30 | Methods and compositions for the treatment of fibrosis |
| EP13718559.1A EP2844253B1 (en) | 2012-04-30 | 2013-04-19 | Tritoqualine for use in the treatment of cystic fibrosis |
| PCT/EP2013/058158 WO2013164204A1 (en) | 2012-04-30 | 2013-04-19 | Tritoqualine for use in the treatment of cystic fibrosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20160328T1 true HRP20160328T1 (hr) | 2016-06-03 |
Family
ID=48184183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20160328TT HRP20160328T1 (hr) | 2012-04-30 | 2016-04-01 | Tritokvalin za uporabu u liječenju cistične fibroze |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9301955B2 (hr) |
| EP (2) | EP2659890A1 (hr) |
| CA (1) | CA2871815C (hr) |
| CY (1) | CY1117620T1 (hr) |
| DK (1) | DK2844253T3 (hr) |
| ES (1) | ES2569391T3 (hr) |
| HR (1) | HRP20160328T1 (hr) |
| HU (1) | HUE027353T2 (hr) |
| IL (1) | IL235358B (hr) |
| PL (1) | PL2844253T3 (hr) |
| RS (1) | RS54733B1 (hr) |
| SI (1) | SI2844253T1 (hr) |
| SM (1) | SMT201600102B (hr) |
| WO (1) | WO2013164204A1 (hr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2790700T3 (es) | 2005-12-28 | 2020-10-28 | Vertex Pharma | Composiciones farmacéuticas de la forma amorfa de N-[2,4-bis(1,1-dimetiletil)-5-hidroxifenil]-1,4-dihidro-4-oxoquinolin-3-carboxamida |
| FR2990859B1 (fr) * | 2012-05-24 | 2014-05-23 | Gaetan Terrasse | Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose |
| JP6963896B2 (ja) * | 2013-11-12 | 2021-11-10 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法 |
| FR3015977B1 (fr) * | 2013-12-30 | 2016-01-01 | Patrice Binay | Chlorhydrate de tritoqualine sous forme cristallisee et procede d'obtention |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| FR3048883B1 (fr) | 2016-03-18 | 2020-10-02 | Gaetan Terrasse | Utilisation d'une molecule h4 agoniste pour le traitement de la fibrose pulmonaire idiopathique |
| FR3096890B1 (fr) * | 2019-06-07 | 2021-05-14 | H4 Orphan Pharma | Utilisation d’une molécule opioïde pour traiter l’œil sec et l’œil allergique. |
| FR3109524B1 (fr) * | 2020-04-22 | 2022-04-08 | H4 Orphan Pharma | Utilisation d’un ligand multifonctionnel pour traiter l’œil sec et les dysfonctionnements des glandes de Meibomius et des glandes lacrymales. |
| FR3111071B1 (fr) | 2020-06-04 | 2023-01-13 | H4 Orphan Pharma | Utilisation de ligands multifonctionnels pour traiter les syndromes de détresse respiratoire et le choc cytokinique liés aux infections virales à coronavirus. |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1988003023A1 (en) * | 1986-10-31 | 1988-05-05 | Mitsubishi Chemical Industries Limited | Drug composition for treating liver diseases and process for its preparation |
| US8207188B2 (en) | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
| WO2007117704A2 (en) | 2006-04-07 | 2007-10-18 | Michalis Nicolaou | Pure isomers of tritoqualine |
| EP2559434A3 (en) | 2007-02-12 | 2013-05-29 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
| EP2318003A1 (en) * | 2008-06-20 | 2011-05-11 | Kinemed, Inc. | Compositions for the treatment of fibrotic diseases or conditions |
-
2012
- 2012-04-30 EP EP12305487.6A patent/EP2659890A1/en not_active Ceased
-
2013
- 2013-04-19 CA CA2871815A patent/CA2871815C/en not_active Expired - Fee Related
- 2013-04-19 DK DK13718559.1T patent/DK2844253T3/en active
- 2013-04-19 EP EP13718559.1A patent/EP2844253B1/en active Active
- 2013-04-19 WO PCT/EP2013/058158 patent/WO2013164204A1/en active Application Filing
- 2013-04-19 SI SI201330160A patent/SI2844253T1/sl unknown
- 2013-04-19 HU HUE13718559A patent/HUE027353T2/en unknown
- 2013-04-19 RS RS20160273A patent/RS54733B1/sr unknown
- 2013-04-19 PL PL13718559.1T patent/PL2844253T3/pl unknown
- 2013-04-19 US US14/397,743 patent/US9301955B2/en not_active Expired - Fee Related
- 2013-04-19 ES ES13718559.1T patent/ES2569391T3/es active Active
-
2014
- 2014-10-27 IL IL235358A patent/IL235358B/en active IP Right Grant
-
2016
- 2016-04-01 HR HRP20160328TT patent/HRP20160328T1/hr unknown
- 2016-04-12 SM SM201600102T patent/SMT201600102B/it unknown
- 2016-04-26 CY CY20161100344T patent/CY1117620T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2844253T3 (pl) | 2016-09-30 |
| SMT201600102B (it) | 2016-07-01 |
| EP2659890A1 (en) | 2013-11-06 |
| HUE027353T2 (en) | 2016-09-28 |
| CA2871815C (en) | 2019-12-24 |
| CA2871815A1 (en) | 2013-11-07 |
| IL235358A0 (en) | 2014-12-31 |
| CY1117620T1 (el) | 2017-04-26 |
| EP2844253B1 (en) | 2016-03-23 |
| EP2844253A1 (en) | 2015-03-11 |
| US9301955B2 (en) | 2016-04-05 |
| DK2844253T3 (en) | 2016-04-18 |
| IL235358B (en) | 2019-09-26 |
| RS54733B1 (sr) | 2016-10-31 |
| WO2013164204A1 (en) | 2013-11-07 |
| ES2569391T3 (es) | 2016-05-10 |
| US20150133487A1 (en) | 2015-05-14 |
| SI2844253T1 (sl) | 2016-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160328T1 (hr) | Tritokvalin za uporabu u liječenju cistične fibroze | |
| ZA202204357B (en) | Alpha-1 antitrypsin (aat) rnai agents, compositions including aat rnai agents, and methods of use | |
| PH12018500765B1 (en) | N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use | |
| UA113165C2 (xx) | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| MX366175B (es) | Composiciones fosfolipidicas terapeuticas concentradas. | |
| MX2013013503A (es) | Composiciones de vancomicina en polvo seco y metodos asociados. | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| MX2014002459A (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos. | |
| WO2011113013A3 (en) | Methods and compositions for treating viral or virally-induced conditions | |
| HK1137807A1 (en) | Diagnosis of infections or inflammatory diseases of the airways and lungs associated with heart failure | |
| MX2018004364A (es) | Acidos pirazolo [3,4-b] piridin-6-carboxilicos sustituidos y su uso. | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| EA201100305A1 (ru) | Лечение респираторных заболеваний | |
| HRP20200661T1 (hr) | Razine ceramida u liječenju i prevenciji infekcija | |
| PH12017502049A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MX2014001088A (es) | Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas. | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| MX344704B (es) | Nanopartículas cargadas con medicamento antitumoral quimioterapéutico. | |
| WO2011141685A3 (fr) | Compositions nasales a visee systemique a base de cocoyl proline ou d'au moins un de ses constituants | |
| MX340138B (es) | Tratamiento de trastornos relacionados con la discinesia. | |
| WO2007098106A3 (en) | Respiratory tract delivery of interferon-tau | |
| WO2014169094A3 (en) | Nhe3-binding compounds and methods for inhibiting phosphate transport | |
| BR112014032239A2 (pt) | inibidores da família de mir-15 de micro-rnas | |
| JP2016512817A5 (hr) | ||
| WO2011055383A3 (en) | Intranasal delivery to improve the performance of children suffering from dyslexia |